Pharmaceuticals R&D Projects
AVG Laboratories is at the forefront of innovative R&D, focusing on developing advanced pharmaceutical dosage forms that address various therapeutic needs, including immediate and modified release profiles, orally disintegrating tablets, and novel delivery systems such as strips.
Pharmaceutical Innovations – Fixed Dose Combinations – Available for OUT-license |
||
| Product developments | Originator/ Tradename | Dossier Status |
| Symptomatic relief of pain and inflammation of the oral mucosa | ||
| Dexamethasone 0.1mg/mL + Lidocaine 20mg/mL – Liquid/Oral Rinse | Added-Value Generic/ Fixed Combination | New Development |
| Treatment of neuropathic pain | ||
| Pregabalin 75-150-300mg + Nortiptyline 25mg | Added-Value Generic/ Fixed Combination | New Development |
| Treatment of overactive bladder (OAB) | ||
| Mirabegron 25-50mg XR + Solifenacin 5mg – Tablet/Capsule | Added-Value Generic/ Fixed Combination | New Development |
| Antiemetic – Prevention of acute and delayed nausea | ||
| Netupitant 30mg/mL + Palonosetron 0.5mg/mL – Liquid | Generic, Helsinn Birex Pharmaceuticals Ltd, “AKYNZEO” | New Development |
| PPI / Treatment of Heartburn | ||
| Omeprazole Delayed Release ODT, 20mg – Tablet | Added-Value Generic/ Fixed Combination | New Development |